Literature DB >> 21609347

Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules.

Min-Kyung Yeo1, Zhe Long Liang, Taejeong Oh, Youngho Moon, Sungwhan An, Min Kyeong Kim, Koon Soon Kim, Minho Shong, Jin-Man Kim, Young Suk Jo.   

Abstract

CONTEXT: Recently, tremendous efforts have been made towards the development of sensitive techniques to detect the BRAF(V600E) mutation in fine needle aspiration biopsy (FNAB) samples. However, newly developed quantitative and semi-quantitative methods, such as dual-priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR), have the potential to generate false-positive (FP) results.
OBJECTIVES: To eliminate the possibility of FP results, we generated a receiver operating characteristic (ROC) curve to investigate the diagnostic accuracy of pyrosequencing using quantitative data.
DESIGN: Cytological diagnoses of 983 thyroid nodules were made according to the Bethesda System 2007. The BRAF(V600E) mutation was analysed by pyrosequencing, and statistical analyses were performed.
RESULTS: Of the 983 nodules, 902 were adopted to evaluate the diagnostic value of pyrosequencing. The number of pathologically confirmed malignancies was 192, of which 182 were papillary thyroid cancer (PTC). By generating an ROC curve, we defined the optimal cut-off value of the mutant allele peak as 5·95% (area under the curve, 0·849; sensitivity, 0·55; 1-specificity, 0). When we applied this selective cut-off value, the number of PTCs positive for BRAF(V600E) was 99 (54·4% of the total number of PTCs). With cytology alone, the diagnostic sensitivity and specificity of detecting malignancy were 71·2% and 100%, respectively. Pyrosequencing improved the diagnostic sensitivity from 71·2% to 78·5% (McNemar's test, P < 0·001), without any change in the diagnostic specificity. When 'suspicious for malignancy' was considered a positive cytological outcome, pyrosequencing increased the diagnostic sensitivity of cytology from 95·8% to 96·9%; however, this improvement did not show statistical significance (McNemar's test, P > 0·05).
CONCLUSIONS: Pyrosequencing is an effective method for detecting the BRAF(V600E) mutation in FNAB samples. By allowing the optimal cut-off value to be determined, pyrosequencing improves the diagnostic sensitivity while eliminating the possibility of FP results.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21609347     DOI: 10.1111/j.1365-2265.2011.04115.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.

Authors:  Jae Young Seo; Eun-Kyung Kim; Jin Young Kwak
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

2.  Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.

Authors:  Jae Won Chang; Ki Wan Park; Jae Hyung Heo; Seung-Nam Jung; Lihua Liu; Sung Min Kim; In Sun Kwon; Bon Seok Koo
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

3.  Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population.

Authors:  Shu Liu; Bingfei Zhang; Yanru Zhao; Pu Chen; Meiju Ji; Peng Hou; Bingyin Shi
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 4.  Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.

Authors:  Pierpaolo Trimboli; Lorenzo Scappaticcio; Giorgio Treglia; Leo Guidobaldi; Massimo Bongiovanni; Luca Giovanella
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

5.  A more sensitive platform for the detection of low-abundance BRAF(V⁶⁰⁰E) mutations.

Authors:  Weiqin Jiang; Weibin Wang; Fangfang Fu; Xiaodong Teng; Haohao Wang; Haiyong Wang; Lisong Teng
Journal:  Mol Cell Biochem       Date:  2012-03-15       Impact factor: 3.396

6.  The diversities in thyroid cytopathology practices among Asian countries using the Bethesda system for reporting thyroid cytopathology.

Authors:  Truong Phan Xuan Nguyen; Vien Thanh Truong; Kennichi Kakudo; Huy Gia Vuong
Journal:  Gland Surg       Date:  2020-10

7.  BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.

Authors:  Anna Guerra; Vincenza Di Stasi; Pio Zeppa; Antongiulio Faggiano; Vincenzo Marotta; Mario Vitale
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

8.  Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis.

Authors:  Ji Hye Park; Hyeong Ju Kwon; Cheong Soo Park; SoonWon Hong
Journal:  Korean J Pathol       Date:  2014-06-26

9.  BRAF V600E mutation correlates with aggressive clinico-pathological features but does not influence tumor recurrence in papillary thyroid carcinoma-10-year single-center results.

Authors:  Navid Tabriz; Johannes Grone; Verena Uslar; Andrea Tannapfel; Dirk Weyhe
Journal:  Gland Surg       Date:  2020-12

10.  Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.

Authors:  Jieun Koh; Jong Rak Choi; Kyung Hwa Han; Eun-Kyung Kim; Jung Hyun Yoon; Hee Jung Moon; Jin Young Kwak
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.